Forget Guessing Earnings—Trade Smarter with the “12:05 Indicator”

Find out its top trade entry for this week

Most people don’t know this… Out of the 500 stocks in the S&P 500… Stocks like Nvidia, Tesla, and Apple - the MAG7 - are the ones really moving the markets. Take a look at this chart of the 20 largest stocks causing 75% of the market volatility: These stocks are causing more than twice the average volatility. And that’s great to know if you love trading the markets as much as I do. It means you have fewer stocks to watch… But you’d better watch them close when they make a big move. And right now we’re on the precipice of what could be a huge breakout… Nvidia is reporting this week… And I want to show you a trick I use to spot big market moves… It doesn’t involve front running news events… Insider info… Or making wild market predictions. It’s a trick I use to make a move AFTER big news has hit the markets… I call it my “12:05 indicator”. See, there’s something strange that happens in the markets around noon… And if you know what to look for, you can spot a breakout before it happens. Just like in May when you could’ve spotted a breakout following a MAG7 earnings report… You didn’t need to speculate on what the report said… Just waited until noon the next trading day… And according to our research, snagged a 106% gain. Then followed it up the very next day with a 158% gain. And then capped off the earnings week with a 96% gain… That’s all thanks to my “12:05 indicator”. Even though there would have been smaller wins and those that did not work out too and I can’t promise future returns or guarantee against losses… My research shows it to have a 78% win rate. That’s much better than a random guess… If you want to learn about how you can access my #1 trading signal for this week, just follow this link.  TBUZ The profits and performance shown today are not typical. We make no future earnings claims, and you may lose money. The performance is based on an internal audit from June 9th, 2023 - November 11th, 2024. The audit took real issued trade alerts from the brand-new Genesis Algorithm and applied a set of options criteria to them, meaning each option gain is hypothetical and uses the benefit of hindsight. From the LIVE trades in real time, so far we have seen a 78% win rate with a 17.8% average winner and a 6.2% average return over a 2 day average hold time.

Most people don’t know this…   Out of the 500 stocks in the S&P 500…   Stocks like Nvidia, Tesla, and Apple - the MAG7 - are the ones really moving the markets.   Take a look at this chart of the 20 largest stocks causing 75% of the market volatility:     These stocks are causing more than twice the average volatility.   And that’s great to know if you love trading the markets as much as I do.   It means you have fewer stocks to watch…   But you’d better watch them close when they make a big move.   And right now we’re on the precipice of what could be a huge breakout…   Nvidia is reporting this week…   And I want to show you a trick I use to spot big market moves…   It doesn’t involve front running news events…   Insider info…   Or making wild market predictions.   It’s a trick I use to make a move AFTER big news has hit the markets…   I call it my “12:05 indicator”.   See, there’s something strange that happens in the markets around noon…   And if you know what to look for, you can spot a breakout before it happens.   Just like in May when you could’ve spotted a breakout following a MAG7 earnings report…   You didn’t need to speculate on what the report said…   Just waited until noon the next trading day…   And according to our research, snagged a 106% gain.     Then followed it up the very next day with a 158% gain.     And then capped off the earnings week with a 96% gain…     That’s all thanks to my “12:05 indicator”.   Even though there would have been smaller wins and those that did not work out too and I can’t promise future returns or guarantee against losses…   My research shows it to have a 78% win rate.   That’s much better than a random guess…   If you want to learn about how you can access my #1 trading signal for this week, just follow this link.    TBUZ   The profits and performance shown today are not typical. We make no future earnings claims, and you may lose money. The performance is based on an internal audit from June 9th, 2023 - November 11th, 2024. The audit took real issued trade alerts from the brand-new Genesis Algorithm and applied a set of options criteria to them, meaning each option gain is hypothetical and uses the benefit of hindsight. From the LIVE trades in real time, so far we have seen a 78% win rate with a 17.8% average winner and a 6.2% average return over a 2 day average hold time.

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Diversified Trading Institute provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Diversified Trading Institute are for your informational purposes only. Neither Diversified Trading Institute nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Diversified Trading Institute is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://www.dtitrader.com/terms-of-service-2/  for our full Terms and Conditions. Unsubscribe This email was sent to phanxuanhoa60.trade1357@blogger.com by Diversified Trading Institute 3929 Airport BLVD, Ste 2-208, Mobile, AL 36609 DTITrader.com

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Diversified Trading Institute provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Diversified Trading Institute are for your informational purposes only. Neither Diversified Trading Institute nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Diversified Trading Institute is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://www.dtitrader.com/terms-of-service-2/  for our full Terms and Conditions. Unsubscribe This email was sent to phanxuanhoa60.trade1357@blogger.com by Diversified Trading Institute 3929 Airport BLVD, Ste 2-208, Mobile, AL 36609 DTITrader.com

Our Top AI Pick of 2025 – It’s not what you think…

Read the full report and find out why. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

A message from NetraMark Holdings Inc.

This is a paid advertisement on behalf of NetraMark Holdings Inc. Please review the forward-looking statements and legal disclaimers at the bottom of our report for important additional information, risk factors, and sources.   Fellow investor,  The pharmaceutical industry spends billions trying to bring new drugs to market—only to see 88% of them fail. But what if a small AI company could change that? That’s exactly what this little-known company is doing – an AI firm that’s poised to transform the way Big Pharma handles clinical trials. By leveraging its revolutionary AI platform, they’re helping drug developers identify which patients respond best to treatment.  It could save time, money, and (most importantly) reduce trial failure rates. That means potentially getting life-saving drugs to market faster and for lower costs. Here’s why you need to know about this: Disruptive AI Technology: This company’s AI platform could become a game-changer for pharmaceutical companies struggling with clinical trial costs. High Potential Returns: With a price tag that's just a fraction of the trial budget, this platform could open the door to multi-million dollar savings. Proven Success: They’ve already secured deals with a major NASDAQ-listed biopharma company, and the ripple effect could be massive. If you want to get in on a potentially lucrative AI opportunity that combines cutting-edge technology with a massive global market, this report is a must-read. Read the full report and find out why we’re naming this company our Top AI Pick of the Year. Please refer to "Important Notice and Disclaimer" at the bottom of our report for important additional information, risk factors, and information sources.

This message is a paid advertisement for NetraMark Holdings Inc. Schaeffer’s Investment Research Inc. receives a fixed fee for distributing this advertisement. Other than the compensation received for this advertisement sent to subscribers, Schaeffer’s Investment Research Inc. and its principals are not affiliated with NetraMark Holdings Inc. Schaeffer’s Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer’s Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer’s Investment Research Inc. to buy or sell any security. Schaeffer’s Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer’s Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NetraMark Holdings Inc. on the NetraMark Holdings Inc. website for additional information. To stop receiving these emails, unsubscribe. Schaeffer's Investment Research 5151 Pfeiffer Road, Suite 450 Cincinnati, Ohio 45242

Congratulations, your seat has been saved!

One more step and you’re good to go!

Hey there… You made the right choice by registering for the NVDA earnings event happening on Wednesday.  When it’s time, Jack, Nate, Roger, Graham, and Kane will share their opinions on what to expect from Nvidia's earnings release. Now, here’s the thing… These top traders have taken their time to single out their favorite AI stock (and it’s not NVDA)...  As it is right now, we’ve put everything in a bonus report – and we want to give it to you, at no cost! All you need to do is watch this video made by Prosperity Pub’s editor-in-chief Stephen Ground… And you’ll have the bonus report texted to you.  What’s more, we’ll send you a private access link when they’re in the LIVE room.  So, make sure you watch this video while you’re still here Talk soon, Your Friends at ProsperityPub

Hey there…   You made the right choice by registering for the NVDA earnings event happening on Wednesday.    When it’s time, Jack, Nate, Roger, Graham, and Kane will share their opinions on what to expect from Nvidia's earnings release.   Now, here’s the thing…   These top traders have taken their time to single out their favorite AI stock (and it’s not NVDA)...    As it is right now, we’ve put everything in a bonus report – and we want to give it to you, at no cost!   All you need to do is watch this video made by Prosperity Pub’s editor-in-chief Stephen Ground…   And you’ll have the bonus report texted to you.    What’s more, we’ll send you a private access link when they’re in the LIVE room.    So, make sure you watch this video while you’re still here Talk soon,   Your Friends at ProsperityPub

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Prosperity Pub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Prosperity Pub are for your informational purposes only. Neither Prosperity Pub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Prosperity Pub is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://prosperitypub.com/terms-conditions/ for our full Terms and Conditions. Unsubscribe This email was sent to phanxuanhoa60.trade1357@blogger.com by Prosperity Pub 101 Marketside Ave, Suite 404 PMB 318, Ponte Vedra, Florida 32081, United States Prosperity Pub

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Prosperity Pub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Prosperity Pub are for your informational purposes only. Neither Prosperity Pub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Prosperity Pub is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://prosperitypub.com/terms-conditions/ for our full Terms and Conditions. Unsubscribe This email was sent to phanxuanhoa60.trade1357@blogger.com by Prosperity Pub 101 Marketside Ave, Suite 404 PMB 318, Ponte Vedra, Florida 32081, United States Prosperity Pub

The Next AI Stocks That Could Breakout...

February 25, 2025 Your exclusive invitation inside… Dear Fellow Investor, I've said it before, and I'll say it again… I believe the stock market is the greatest wealth creation machine in history! Investors have used stocks as a tool to build wealth (over a long period of time) for decades and decades… But right now, there is a unique window of opportunity for those in-the-know to gain wealth in a much shorter period of time… That is – if you're able to pick the right stocks! Nvidia and other AI-related stocks have been an excellent investment for many in the last few years… And now, my team and I are ready to reveal my #1 strategy for finding stocks that outperform today's market! During my upcoming Unbreakable Investor LIVE Event, we'll be walking through: How I select the stocks on my private watchlist AND buy list The strategic advantage we're using in 2025 – and beyond PLUS we'll be analyzing some of YOUR stocks LIVE during the event! Registration for this event is 100% free, but spots are filling up quickly. Make sure you click here to reserve your seat now. Regards, PS - Everyone who attends will also receive 2 special FREE Gifts after the event. You can find out what they are by clicking here now. *Individual results are not typical. Past performance is not an indication of future results. Your results may vary.   Update your email preferences or unsubscribe here © 2025 Millionaire Publishing 66 W Flagler St. Ste. 900 Miami, FL 33130, United States of America Terms of Service

Actuate Therapeutics (NASDAQ: ACTU) Triggers 17 Bullish Signals On Phase 2 Trial News

*Sponsored Market Crux Announces Actuate Therapeutics, Inc. (NASDAQ: ACTU) As Its Next Potential Breakout Idea… Here’s Why… Limited Share Availability: With a low float (<6M shares) and strong insider control (65%), this structure has the potential for volatility if demand begins to shift. Ongoing Clinical Trials: Actuate Therapeutics, Inc. (NASDAQ: ACTU) continues to evaluate elraglusib’s effectiveness in treating multiple cancer types. Key Event This Week: The B. Riley Oncology Conference on February 28th could bring important updates on Actuate Therapeutics, Inc. (NASDAQ: ACTU)’s clinical progress and research developments. Consider taking a look at (ACTU) before the bell rings… February 25, 2025 Dear Reader, Are you watching Actuate Therapeutics, Inc. (NASDAQ: ACTU) this morning? (ACTU) came out of the gate straight away Triggering 17 Bullish Signals on TradingView’s technical analysis tool, including the Momentum Indicator, using the 5 minute time-frame. Actuate Therapeutics, Inc. (NASDAQ: ACTU) Just Lit Up The Following Indicators: Average Directional Index (14) Momentum (10) MACD Level (12, 26) Exponential Moving Average (10) Simple Moving Average (10) Exponential Moving Average (20) Simple Moving Average (20) Exponential Moving Average (30) Simple Moving Average (30) Exponential Moving Average (50) Simple Moving Average (50) Exponential Moving Average (100) Simple Moving Average (100) Exponential Moving Average (200) Simple Moving Average (200) Volume Weighted Moving Average (20) Hull Moving Average (9) (ACTU) is currently trending above its 5-Day moving average of 7.81, but with its 20-Day moving average at 8.43, we have all eyes on it right now. Actuate Therapeutics, Inc. (NASDAQ: ACTU) reached $8.50 earlier, making an approximate 15% move from yesterday’s $7.34 close.  Earlier today, Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced the completion of patient enrollment in its Phase 2 trial evaluating elraglusib (9-ING-41) in combination with FOLFIRINOX and losartan for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). This milestone marks a significant step forward in the development of potentially more effective treatment options for one of the most challenging cancers. Key Highlights of the Announcement: ✔ Patient Enrollment Completed: 56 treatment-naïve mPDAC patients have been enrolled in this Phase 2 open-label, non-comparator study (NCT05077800). ✔ Early Clinical Activity Observed: Initial data presented at the AACR Special Conference on Advances in Pancreatic Cancer Research (Sept. 2024) revealed early evidence of enhanced clinical activity when elraglusib was combined with FOLFIRINOX and losartan in untreated mPDAC patients. ✔ Final Results Expected in 2026. ✔ Lead Investigator & Research Sites: The trial is led by Dr. Colin Weekes, MD, Ph.D. (Massachusetts General Hospital) with participation from University of Colorado (Dr. Cristopher Lieu, MD) and Fred Hutchinson Cancer Center (Dr. Andrew Coveler, MD). A Critical Step in Advancing Elraglusib Actuate Therapeutics, Inc. (NASDAQ: ACTU)’s President & CEO, Daniel Schmitt, emphasized the importance of this trial in establishing elraglusib as a promising new therapy for pancreatic cancer.  The company’s interim Phase 2 data from another study combining elraglusib with gemcitabine/nab-paclitaxel (GnP) has already demonstrated statistically significant improvements in 1-year and median overall survival in first-line mPDAC treatment. Dr. Weekes and his research team believe that the insights gained from this trial could contribute to the development of more effective treatments for metastatic pancreatic cancer. With pancreatic cancer being one of the most aggressive and deadly forms of cancer, this trial represents a meaningful step forward in research and treatment innovation. If you missed my earlier email on (ACTU), keep reading below to get caught up to speed before the bell rings. Today, the spotlight is on Actuate Therapeutics, Inc. (ACTU)—a clinical-stage biopharmaceutical company focused on developing breakthrough cancer treatments designed to address some of the toughest, most treatment-resistant cancers. Key Factors to Watch for (ACTU) Today With less than 6M shares in the float and over 65% insider ownership, (ACTU) has a tightly held structure that can lead to sharp movement if demand begins to shift.  A strong level of insider control suggests confidence in the company’s direction, while a low float can contribute to significant swings under certain conditions. Recent Market Recognition Actuate Therapeutics, Inc. (NASDAQ: ACTU) has seen strong market attention in recent weeks, posting a move of approximately 87% in about a month. December 23, 2024: (ACTU) was trending at at $6.27 January 23, 2025: (ACTU) reached $11.73 Now: (ACTU) is currently trending above its 5-day moving average of $7.67 after reaching $8.00 in pre-market trading today. This type of momentum suggests increased interest, particularly as the company moves forward with its clinical developments and upcoming events. Upcoming Event – February 28, 2025 Daniel Schmitt, President & CEO of Actuate Therapeutics, Inc. (NASDAQ: ACTU), will participate in the: B. Riley Precision Oncology & Radiopharma Conference Date: Friday, February 28, 2025 Location: New York, NY Format: Fireside chat + one-on-one meetings This event could bring key updates on clinical progress and provide further insights into Actuate’s work in developing novel therapies for treatment-resistant cancers. Advancing Cancer Research with a Unique Approach Actuate Therapeutics, Inc. (NASDAQ: ACTU) is working to develop treatments that go beyond conventional chemotherapy and radiation.  Its lead candidate, Elraglusib, is a GSK-3β inhibitor designed to disrupt cancer survival mechanisms and make tumors more responsive to treatment. How Elraglusib Targets Cancer Cells Many cancers become resistant to traditional treatments by activating DNA Damage Response (DDR) pathways, allowing tumors to repair themselves after chemotherapy or radiation.  Elraglusib blocks GSK-3β, an enzyme that supports these survival mechanisms. By interfering with this process, it may: ✅ Reduce cancer cell survival and proliferation ✅ Enhance the effectiveness of chemotherapy and radiation ✅ Limit the ability of tumors to recover from treatment A Dual Effect: Weakening Tumors & Engaging the Immune System Elraglusib is being studied not just for its direct impact on tumors but also for its role in supporting the body’s natural immune defense against cancer. Blocking NF-kB: Many aggressive cancers use NF-kB, a key protein complex, to suppress immune response and fuel tumor growth. Elraglusib works by inhibiting NF-kB, potentially restoring immune function and making tumors more vulnerable. Regulating Immune Checkpoints: Cancer cells often evade detection by manipulating immune checkpoints—molecular signals that tell the immune system to stand down. Elraglusib may help regulate these checkpoints, potentially enhancing the effectiveness of immune-based therapies. What’s Next for Actuate Therapeutics, Inc. (NASDAQ: ACTU)? With an innovative approach that combines direct tumor targeting with immune system support, Elraglusib represents a significant step forward in cancer research. Ongoing Clinical Trials: Actuate Therapeutics, Inc. (NASDAQ: ACTU) continues to evaluate elraglusib’s effectiveness in treating multiple cancer types. Limited Share Availability: With a low float (<6M shares) and strong insider control (65%), this structure has the potential for volatility if demand begins to shift. Key Event This Week: The B. Riley Oncology Conference on February 28th could bring important updates on Actuate Therapeutics, Inc. (NASDAQ: ACTU)’s clinical progress and research developments. With its focus on tackling treatment-resistant cancers and advancing new scientific approaches, Actuate Therapeutics, Inc. (NASDAQ: ACTU) is at the forefront of a rapidly evolving field.  Those following developments in medical research and breakthrough treatments will be watching closely. We have all eyes on Actuate Therapeutics, Inc. (NASDAQ: ACTU) right now. As soon as the bell rang, (ACTU) came out of the gate straight away, triggering 17 Bullish Signals on TradingView’s technical analysis tool, including the Momentum Indicator. Remember, earlier today, Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced the completion of patient enrollment in its Phase 2 trial.  Are you watching (ACTU) yet? Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 02/25/2025 and ending on 02/25/2025 to publicly disseminate information about (ACTU:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their members own shares of (ACTU:US). Please see important disclosure information here: https://marketcrux.com/disclosure/actu/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice